Abstract:Highlights • This study highlights the benefits of integrating microneedle (MN) technologies with the nanoemulsion (NE) system represents a promising approach to enhance the transdermal delivery of estradiol valerate (E2V), a hydrophobic drug with a Log P of 6.62. • E2V-NE formulations and core-shell dissolving microneedles (CS-dMNs) were developed utilizing a computational design strategy. • Developed self-administered E2V-NE-loaded CS-dMNs offering a convenient platform for achieving long-acting and controlled hormone levels in clinical response dosages. Estradiol valerate (E2V) is a hormone utilized for estrogen replacement therapy. Nonetheless, its application in pharmaceutical formulations has been limited due to its poor solubility in water and suboptimal efficacy for transdermal drug delivery. Hence, the combination of nanoemulsions (NEs) with core-shell dissolving microneedles (CS-dMNs), which encase the drug, represents a promising approach to enhance transdermal drug delivery while ensuring controlled release. This study aimed to develop E2V-NE-loaded CS-dMNs for achieving controlled transdermal release of E2V. The E2V-NEs were formulated and evaluated for parameters including droplet size, polydispersity index (PDI), and zeta potential. Subsequently, these E2V-NEs were integrated into the core of CS-dMNs. The physical and mechanical properties of E2V-NE-loaded CS-dMNs were evaluated, along with parameters such as detachment time, drug content, in vitro and in vivo skin permeation, and safety. The results indicated that E2V-NE-loaded CS-dMNs exhibited favorable physical and mechanical characteristics, enabling easy self-administration with patch detachment after 30 min, while ensuring controlled drug release from the core of dMNs. The E2V content in CS-dMNs was determined to be 0.76 ± 0.15 mg/patch. Furthermore, in vitro and in vivo skin permeation studies demonstrated a synergistic effect between NEs and MNs, achieving therapeutic drug levels sustained over a week (368.54 ± 67.93 μg/mL in in vitro and 697.45 ± 270.10 pg/mL in in vivo), with no indications of infection and complete skin healing observed within 8 h. Consequently, E2V-NE-loaded CS-dMNs present a promising alternative for achieving sustained and controlled hormone levels conveniently. Graphical abstract Download : Download high-res image (242KB) Download : Download full-size image

Fabrication of controlled-release polymeric microneedles containing progesterone-loaded self-microemulsions for transdermal delivery

Preparation and In Vitro Characterization of Microneedles Containing Inclusion Complexes Loaded with Progesterone

Intradermal Implantable PLGA Microneedles for Etonogestrel Sustained Release

Computer-aided design and optimization of estradiol valerate nanoemulsion-loaded core-shell microneedle patches for controlled release transdermal drug delivery

Polymeric Microneedle-Mediated Sustained Release Systems: Design Strategies and Promising Applications for Drug Delivery.

PEGDA/PVP Microneedles with Tailorable Matrix Constitutions for Controllable Transdermal Drug Delivery

Hydrogel Microneedles with Programmed Mesophase Transitions for Controlled Drug Delivery

Fabrication, Physicochemical Characterization, and Performance Evaluation of Biodegradable Polymeric Microneedle Patch System for Enhanced Transcutaneous Flux of High Molecular Weight Therapeutics

Two Photon Polymerization-Micromolding of Polyethylene Glycol-Gentamicin Sulfate Microneedles

Polymeric Microneedles Enhance Transdermal Delivery of Therapeutics

Polymeric Microneedles for Transdermal Protein Delivery

Formulation and characterization of thiolated chitosan/polyvinyl acetate based microneedle patch for transdermal delivery of dydrogesterone

Fabrication of Poly Lactic- co-Glycolic Acid Microneedles for Sustained Delivery of Lipophilic Peptide-Carfilzomib

Polymer homologue-mediated formation of hydrogel microneedles for controllable transdermal drug delivery

Self‐Healing Porous Microneedles Fabricated Via Cryogenic Micromoulding and Phase Separation for Efficient Loading and Sustained Delivery of Diverse Therapeutics

Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery

Transdermal drug delivery system through polymeric microneedle: A recent update

Incorporating surfactants into PCL microneedles for sustained release of a hydrophilic model drug

Design, optimization, and evaluation for a long-time-released transdermal microneedle delivery system containing estradiol

Fabrication and Evaluation of Transdermal Delivery of Carbamazepine Dissolving Microneedles

Dissolvable microneedles for transdermal drug delivery showing skin pentation and modified drug release